ClinicalTrials.gg
RecruitingNCT04319627SAVERUpdated Jan 15, 2026

Statins for Venous Event Reduction in Patients With Venous Thromboembolism

A Phase 3 interventional study of Rosuvastatin Calcium and Placebo Oral Tablet in Venous Thromboembolism, Blood Clot and Post Thrombotic Syndrome, sponsored by Ottawa Hospital Research Institute. Recruiting at 31 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Ottawa Hospital Research Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,700
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Venous Thromboembolism by Ottawa Hospital Research Institute — 6 open to participants now, 6 under way, 5 of them phase 3. Venous Thromboembolism · Ottawa Hospital Research Institute.

Planned enrollment
2nd of 15
2,700 · median 312
Started
2021
with 2 others
Phase 3
5 of 21
4 open now
Registered
15th of 21
by date

Among the 21 studies in Venous Thromboembolism by Ottawa Hospital Research Institute, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 15th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

6 of the 21 studies in Venous Thromboembolism by Ottawa Hospital Research Institute are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Venous Thromboembolism by Ottawa Hospital Research Institute, or all of them as a file.
02

Study summary

The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants).

While treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming.

The medication in this study, rosuvastatin, is approved in Canada for use as a cholesterol-lowering medication. The use of rosuvastatin in this study is considered investigational. This means that Health Canada has not approved the use of rosuvastatin as a treatment for blood clots. However, it has been approved for use in this research study.

The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. The investigators also hope to discover if taking a statin reduces damage to your veins. To do this, some of the participants in this study will get rosuvastatin and others will receive a placebo (a substance that looks like the study rosuvastatin but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your blood clot. A placebo is used to make the results of the study more reliable.

Read the detailed description

Recent research has demonstrated that it is plausible that statins have additive, and potentially even synergistic effects, in reducing recurrent VTE in patients managed with anticoagulant-based strategies. Furthermore, it is plausible that statins may reduce the risk of recurrent VTE in those not on anticoagulants and therefore offer an alternative in patients with contraindications to anticoagulants (e.g. after major intracranial bleed), who refuse to take anticoagulants long-term (e.g. due to lifestyle modifications or fear of bleeding) or who cannot afford anticoagulants (e.g. vulnerable or impoverished populations). Finally, statins may also provide protection from recurrent VTE in patients who are not fully compliant with anticoagulant therapy. However, no known RCTs have been done to explore these possibilities.

This study aims to determine if generic rosuvastatin reduces the risk of recurrent VTE compared to placebo in patients with symptomatic major VTE.

Primary Objectives

- To determine the primary outcome event rate (i.e. symptomatic recurrent major VTE [proximal DVT or segmental or larger PE]) in patients taking generic rosuvastatin compared to placebo.

Secondary Objectives

  • To determine the major bleeding event rate in patients taking generic rosuvastatin compared to placebo.
  • To explore if rosuvastatin reduces the incidence of PTS, as measured by the Villalta scale at end of study.
03

Conditions studied

  • Venous Thromboembolism
  • Blood Clot
  • Post Thrombotic Syndrome

Keywords

  • Rosuvastatin
  • Statin
  • PTS
  • VTE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Symptomatic objectively confirmed proximal leg DVT (above the trifurcation of the popliteal vein) and/or PE (segmental or greater) diagnosed in the last 30 days.

Exclusion criteria

Exclusion criteria

  1. Unable or unwilling to provide written ;
  2. \< 18 years of age;
  3. Women of unwilling to use appropriate ;
  4. Currently prescribed a statin;
  5. A known medical history or current diagnosis of any of the following for which statins are indicated in secondary prevention:

    1. Diabetes;
    2. Abdominal aortic aneurysm;
    3. Peripheral arterial disease;
    4. Stroke;
    5. (TIA);
    6. Myocardial infarction (MI);
    7. Acute coronary syndromes;
    8. Stable/unstable angina;
    9. Coronary or other arterial revascularization;
  6. Known diagnosis of hypercholesterolemia or dyslipidemia;
  7. to rosuvastatin;

    1. Known or intolerance to statins;
    2. History of muscle disorders or statin-related muscle pain;
    3. Known liver disease (active liver disease, e.g. Hepatitis A, B, C, non-alcoholic fatty liver);
    4. Chronic kidney disease ( \< 30ml/min);
    5. Currently pregnant or breast feeding;
    6. Taking cyclosporine;
    7. Taking atazanavir/ritonavir;
    8. Taking darolutamide;
    9. Taking regorafenib;
  8. Unstable medical or psychological condition that would interfere with trial participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,700 participants (estimated)

Study arms

  • Experimental
    Rosuvastatin

    Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.

    Drug: Rosuvastatin Calcium

  • Placebo comparator
    Placebo

    Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.

    Drug: Placebo Oral Tablet

Interventions

  • DrugRosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.

    Also known as: Rosuvastatin

  • DrugPlacebo Oral Tablet

    Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Recurrent Major VTE

    Symptomatic recurrent major VTE (proximal DVT or segmental or larger PE) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.

    Time frame: Up to 60 months

Secondary outcomes

  1. Post Thrombotic Syndrome

    Post-thrombotic syndrome as measured by the Villalta scale throughout the follow-up period in patients taking generic rosuvastatin as compared with placebo. The Villalta PTS scale has been adopted by the International Society on Thrombosis and Haemostasis (ISTH) as a standard to diagnose and grade the severity of PTS in clinical studies. Points are summed to yield total score: 0-4: No PTS; 5-9: Mild PTS; 10-14: Moderate PTS; 15 or more, or presence of ulcer: Severe PTS.

    Time frame: Up to 60 months

  2. Number of participants diagnosed with non-major VTE during follow-up

    Symptomatic non-major VTE (see below) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo. Non-major VTE: * Distal DVT (distal to the trifurcation of the popliteal vein); * Isolated sub-segmental PE; * Upper extremity DVT; * Superficial phlebitis \> 5 cm; * Superficial phlebitis ≤ 5 cm.

    Time frame: Up to 60 months

  3. Number of participants diagnosed with an arterial vascular event during follow-up

    Components of composite arterial vascular events (see below) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo. Components of composite arterial vascular events: * Fatal myocardial infarction; * Non-fatal myocardial infarction; * Hospitalization for unstable angina; * Coronary artery revascularization; * Sudden cardiac death; * Ischemic stroke.

    Time frame: Up to 60 months

  4. Number of deaths during study participation

    All-cause mortality occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.

    Time frame: Up to 60 months

Other outcomes

  1. Number of participants who have a bleeding event during follow-up

    Bleeding event (major, clinically relevant non-major, minor) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.

    Time frame: Up to 60 months

07

Study locations

19 of 31 sites recruiting
  • Foothills Medical Centre
    Calgary, Alberta T2N 2T9, Canada
    Recruiting
    • Leslie Skeith, MD · Principal investigator
  • Queen Elizabeth II Hospital
    Halifax, Nova Scotia B3H 2Y9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hamilton General Hospital
    Hamilton, Ontario L8L 2X2, Canada
    Recruiting
    • Sam Schulman, MD · Principal investigator
  • St. Joseph's Healthcare
    Hamilton, Ontario L8N 4A6, Canada
    Recruiting
    • Jim Douketis, MD · Principal investigator
  • Juravinski Hospital
    Hamilton, Ontario L8V 1C3, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Jennifer Brinkhurst · Contactjbrinkhurst@ohri.ca
    • Aurélien Delluc, MD · Principal investigator
  • Hôpital Montfort
    Ottawa, Ontario K1K 0T2, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Niagara Health - St. Catharines Site
    St. Catharines, Ontario L2S 0A9, Canada
    Recruiting
    • Blair Leonard, MD · Principal investigator
  • Sunnybrook Hospital
    Toronto, Ontario M4N 3M5, Canada
    Not yet recruiting
    • Jean-Philippe Galanaud, MD · Principal investigator
  • University Health Network
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
    • Erik Yeo, MD · Principal investigator
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
    • Susan Kahn, MD · Principal investigator
  • McGill Univeristy Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Véronique Naessens, MD · Principal investigator
  • CIUSSS de-l'Ouest-de-l'Ile-de-Montreal -St. Mary's Hospital Center
    Montreal, Quebec H9R 2Y2, Canada
    Recruiting
    • Carolyne Elbaz, MD · Principal investigator
  • CHU de Quebec-Université Laval
    Québec, Quebec G1V 4G2, Canada
    Recruiting
    • Guillaume Roberge, MD · Principal investigator
  • CHU d'Angers - Service d'accueil et traitement des Urgences
    Angers, France
    Recruiting
    • Jeane Hersant · Principal investigator
  • Brest University Hospital Centre
    Brest, France
    Recruiting
    • Raphael Le Mao, MD · Principal investigator
  • CHU de Clermont-Ferrand, Hôpital Gabriel Montpied
    Clermont-Ferrand, France
    Recruiting
    • Jeanot Schmidt, MD · Principal investigator
  • APHP Hôpital Louis Mourier
    Colombes, France
    Recruiting
    • Isabelle Mahe · Principal investigator
  • CHU de Dijon - Service d'imagerie diagnostique et thérapeutique
    Dijon, France
    Recruiting
    • Nicolas Falvo · Principal investigator
  • GH La Rochelle - Ré-Aunis - Service de Médecine vasculaire
    La Rochelle, France
    Recruiting
    • Christophe Roncato · Principal investigator
  • Centre Hospitalier Universitaire De Saint Etienne
    Saint-Etienne, France
    Recruiting
    • Laurant Bertoletti, MD · Principal investigator
  • CHI Toulon - La Seyne sur Mer - Hôpital Sainte Musse
    Toulon, France
    Recruiting
    • Jean-Noël Poggi · Principal investigator
  • Mater Misericordiae University Hospital
    Dublin, Ireland
    Not yet recruiting
    • Fionnuala Ní Áinle, MD · Principal investigator
  • University of Insubria
    Varese, Italy
    Not yet recruiting
    • Walter Ageno, MD · Principal investigator
  • Ostfold Hopsital
    Sarpsborg, Norway
    Recruiting
    • Sven Arne Sogn · Contact
    • Waleed Ghanima, MD · Principal investigator
  • Aberdeen Royal Infirmary
    Aberdeen, United Kingdom
    Not yet recruiting
    • Mary-Joan Macleod · Principal investigator
  • Queen Elizabeth Hospital
    Birmingham, United Kingdom
    Not yet recruiting
    • Gillian Lowe · Principal investigator
  • University Hospital of Wales
    Cardiff, United Kingdom
    Not yet recruiting
    • Raza Alikhan · Principal investigator
  • Glasgow Royal Infirmary
    Glasgow, United Kingdom
    Not yet recruiting
    • Catherine Bagot · Principal investigator
  • King's College Hospital NHS Foundation Trust
    London, United Kingdom
    Not yet recruiting
    • Lara Roberts · Principal investigator
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, United Kingdom
    Not yet recruiting
    • Nicola Curry · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Jan 2028, 83 months after the start.

Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2020
First posted
Mar 24, 2020
StartActual
Feb 10, 2021
Primary completionEst.
Jan 2028
CompletionEst.
Apr 2028
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04319627
Collaborators
Canadian Institutes of Health Research (CIHR), Eastern Norway Health Authorities RHF, Southern health region, Norway, Programme hospitalier de recherche clinique, France, British Heart Foundation
Responsible party
Sponsor
First posted
Mar 24, 2020
Start date
Feb 10, 2021
Primary completion
Jan 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jan 15, 2026

Study contacts

Jennifer Brinkhurst
Contact
jbrinkhurst@ohri.ca
613-737-8899
OHRI Clinical Research Quality Team
Contact
CRQuality@ohri.ca
Aurélien Delluc, MD
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion